Authors
Latest:
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based ProductsAs the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
Latest:
The Future of Personalized Medicine Hinges on Pharma Executives Revolutionizing Business ModelsThe era of big pharma as product-first companies must end, as services become the larger priority.
Latest:
Beyond the Prescription: The Role Pharma Plays in Digital Health ConversationsAs social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
Latest:
Examining Data Breaches in Pharma Companies During COVID-19Pharma companies are struggling to maintain a high level of cybersecurity amidst the pandemic.
Latest:
How Leaders Can Empower Their People to be Their BestIf you wish for your team to be diligent, innovative, and collaborative, you must first exhibit these traits yourself
Latest:
Embracing the Renaissance of Small Molecule Drug DiscoveryPharma companies may benefit from meeting challenges and embracing small molecule drug discovery.
Latest:
Strategic Commercialization of Multi-Indication Obesity Therapies: Balancing Early Access, Pricing, and Lifecycle ValueThe regulatory environment has become increasingly supportive of multi-indication development.
Latest:
Four Key Strategies for Optimizing Your Medical Congress StrategyConferences, congresses, and the digital discussions kicked off by those events create a halo effect that amplifies scientific information more so than other scientific activities.
Latest:
Beyond the Data: Making HCP Analytics Actually Work for Commercial TeamsTraditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.
Latest:
Operating Models for Successful DOL EngagementHow life sciences companies can design an effective operating model for DOL engagements.
Latest:
Accelerating Rare Disease Drug Development with NLP: Three Use CasesUtilizing natural language processing technologies to improve search capabilities and advance the development of therapies.
Latest:
How Does the Shift to Early-Stage M&A Change Due Diligence?A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.
Latest:
Bridging the Divide: Medical's Omnichannel MomentumHow pharma medical affairs and commercial teams are synchronizing their capabilities to boost omnichannel marketing strategies and better understand customer engagement needs.
Latest:
Exploring the Advantages of Innovative Early Phase Trial DesignIn early phase trials innovative designs offer potential for improvements in efficiency and decision-making.
Latest:
Bridging the Gap Between AI-Powered Medical Imaging and Clinical Decision-Making in Precision Oncology: Are we there yet?Bridging the last mile to clinical actionability.
Latest:
A Brave New World: Optimizing Access in Wake of COVIDThe top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.
Latest:
The Future of Medicine is SmartThis white paper describes how digitizing medicines can drive patient engagement, reduce non-adherence, and enhance supply chain visibility.
Latest:
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent ContractorsPharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Latest:
The Value Cornerstone: Bridging the Pharma Marketing GapBrand positioning that targets HCPs is often irrelevant to the payer mindset. Fortunately, market access teams have an option, writes Ed Shankman.
Latest:
Foundational Questions in Data Reporting, Analytics to Meet Reimbursement-Directed Marketing GoalsMeasuring the relationship between a product’s reimbursement position and performance begins with gathering key data points for as many products as possible.
Latest:
Staying the Course: Double Down on Launch AgilityIn today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.
Latest:
Health Equity Barriers in Oncology TrialsOvercoming persistent barriers to health equity in oncology trials will require innovation and cooperation.
Latest:
Leveraging Technology for Pharmaceutical CommercializationWith AI/ML and cognitive technologies set to become a key enabler of the pharma commercialization process, Srini Rajamani outlines how pharma companies can leverage tech effectively.
